ATE473747T1 - NEUE VERWENDUNG DES MIFEPRISTON UND DESSEN DERIVATEN ZUR MODULIERUNG DES ßHEDGEHOGß- PROTEINSIGNALWEGES UND DESSEN ANWENDUNGEN - Google Patents

NEUE VERWENDUNG DES MIFEPRISTON UND DESSEN DERIVATEN ZUR MODULIERUNG DES ßHEDGEHOGß- PROTEINSIGNALWEGES UND DESSEN ANWENDUNGEN

Info

Publication number
ATE473747T1
ATE473747T1 AT04704259T AT04704259T ATE473747T1 AT E473747 T1 ATE473747 T1 AT E473747T1 AT 04704259 T AT04704259 T AT 04704259T AT 04704259 T AT04704259 T AT 04704259T AT E473747 T1 ATE473747 T1 AT E473747T1
Authority
AT
Austria
Prior art keywords
steroid
modulating
signaling pathway
protein signaling
aralkyl
Prior art date
Application number
AT04704259T
Other languages
English (en)
Inventor
Martial Ruat
Elisabeth Traiffort
Helene Faure
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE473747T1 publication Critical patent/ATE473747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT04704259T 2003-01-22 2004-01-22 NEUE VERWENDUNG DES MIFEPRISTON UND DESSEN DERIVATEN ZUR MODULIERUNG DES ßHEDGEHOGß- PROTEINSIGNALWEGES UND DESSEN ANWENDUNGEN ATE473747T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300646A FR2850022B1 (fr) 2003-01-22 2003-01-22 Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
PCT/FR2004/000151 WO2004067550A2 (fr) 2003-01-22 2004-01-22 Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications

Publications (1)

Publication Number Publication Date
ATE473747T1 true ATE473747T1 (de) 2010-07-15

Family

ID=32605913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704259T ATE473747T1 (de) 2003-01-22 2004-01-22 NEUE VERWENDUNG DES MIFEPRISTON UND DESSEN DERIVATEN ZUR MODULIERUNG DES ßHEDGEHOGß- PROTEINSIGNALWEGES UND DESSEN ANWENDUNGEN

Country Status (8)

Country Link
US (1) US8703752B2 (de)
EP (1) EP1585526B1 (de)
JP (1) JP4667363B2 (de)
AT (1) ATE473747T1 (de)
CA (1) CA2513717C (de)
DE (1) DE602004028098D1 (de)
FR (1) FR2850022B1 (de)
WO (1) WO2004067550A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8716479B2 (en) 2007-12-27 2014-05-06 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
AR070047A1 (es) * 2007-12-27 2010-03-10 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
FR2948367A1 (fr) 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
US20110065645A1 (en) * 2009-09-10 2011-03-17 The Regents Of The University Of California Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011150209A1 (en) * 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
WO2012138857A2 (en) 2011-04-08 2012-10-11 Mayo Foundation For Medical Education And Research Methods and materials for reducing supression of immune function
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
CA2856291C (en) * 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US20130274233A1 (en) * 2012-04-03 2013-10-17 President And Fellow Of Harvard College Modulators of hedgehog signaling pathway
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
EP2925363A4 (de) * 2012-11-29 2016-11-09 Strasspharma Llc Verfahren zur modulation einer follikelstimulierenden hormonaktivität
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
DK3003309T3 (da) 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
EP3052485B1 (de) 2013-10-04 2021-07-28 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und verwendungen davon
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (de) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (de) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Hemmer von cyclinabhängigen kinasen
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
TWI814925B (zh) 2018-10-29 2023-09-11 美商湛新美國股份有限公司 低烘烤粉末塗料樹脂及塗覆基材的方法
KR102544591B1 (ko) * 2023-02-08 2023-07-17 주식회사 에스씨엘테라퓨틱스 신규 화합물 및 이의 용도
KR102604396B1 (ko) * 2023-02-08 2023-11-23 주식회사 에스씨엘테라퓨틱스 신규 화합물 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5759811A (en) * 1996-11-13 1998-06-02 The Regents Of The University Of California Mutant human hedgehog gene
AU5729098A (en) * 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
JP2002504895A (ja) * 1997-04-28 2002-02-12 ザ ユニバーシティー オブ ブリティッシュコロンビア アミロイド症を調節する方法及び組成
CN1218665A (zh) * 1997-12-03 1999-06-09 上海市计划生育科学研究所 高效米非司酮制剂、其制备方法和用途
US6277566B1 (en) * 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
AU756818B2 (en) * 1998-05-15 2003-01-23 Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
AU4416499A (en) * 1998-06-03 1999-12-20 President And Fellows Of Harvard College, The Use of bigenic mouse models and assay systems to identify agents that regulate proliferation and differentiation
JP2003501395A (ja) * 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
AU9684401A (en) * 2000-10-13 2002-04-22 Curis Inc Hedgehog antagonists, methods and uses related thereto

Also Published As

Publication number Publication date
EP1585526B1 (de) 2010-07-14
DE602004028098D1 (de) 2010-08-26
JP2006516289A (ja) 2006-06-29
CA2513717C (fr) 2012-04-17
JP4667363B2 (ja) 2011-04-13
US20070060546A1 (en) 2007-03-15
WO2004067550A2 (fr) 2004-08-12
EP1585526A2 (de) 2005-10-19
FR2850022A1 (fr) 2004-07-23
CA2513717A1 (fr) 2004-08-12
WO2004067550A3 (fr) 2004-10-14
FR2850022B1 (fr) 2006-09-08
US8703752B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
ATE473747T1 (de) NEUE VERWENDUNG DES MIFEPRISTON UND DESSEN DERIVATEN ZUR MODULIERUNG DES ßHEDGEHOGß- PROTEINSIGNALWEGES UND DESSEN ANWENDUNGEN
BRPI0817096A8 (pt) Análogo de tiazolidinodiona e composição farmacêutica que o compreende
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
BRPI0409680A (pt) análogos de fosfonato anti-cáncer
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
BRPI0515412A (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
BRPI0508047A (pt) derivados de alquilpiperazina-e alquil-homopiperazina-carboxilatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah
BR0314544A (pt) Compostos para a inibição de rotamases e seu uso
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
ATE451351T1 (de) Vitamin-d-analogon nel, verfahren und seine verwendung
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
AR078948A1 (es) Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
UY28839A1 (es) Agentes terapeuticos
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
AR050341A1 (es) Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos
BRPI0912171B8 (pt) composto ativador de receptor de glicocorticoide, e, composição
AR044883A1 (es) Derivados del 8-aza-biciclo [3.2.1] octano y su uso como inhibidores de la recaptacion de neurotransmisores monoaminicos
UY28911A1 (es) Profármacos de esteroides con acción androgénica
AR059546A1 (es) Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
BR112012009861A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR9707601A (pt) Composição farmacêutica para tratar de um distúrbio hepático e composto derivado de triterpeno.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties